Inactive Instrument

Aerpio Pharmaceuticals

ARPO

US00810B1052

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

October 26, 2020 at 04:01 pm EDT

Aerpio Pharmaceuticals, Inc. reported dosing of its first patient in the Phase 2 trial targeting the prevention and treatment of ARDS in patients with moderate-to severe COVID-19.

Latest news about Aerpio Pharmaceuticals

Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut	21-08-27	MT
Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index	21-08-27	CI
Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	21-08-25	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
North American Morning Briefing : Stock Futures -3-	21-07-09	DJ
AERPIO PHARMACEUTICALS : HC Wainwright Upgrades Aerpio Pharmaceuticals to Buy from Neutral on 'Transformative' Aadi Merger, Sets $22 Price Target	21-07-08	MT
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Aerpio Pharmaceuticals : Earnings Flash (ARPO) AERPIO PHARMACEUTICALS Reports Q1 Loss $-0.09	21-05-17	MT
Aerpio Pharmaceuticals : Aadi Bioscience to Merge Into Combined Listed Company	21-05-17	MT
Aadi Bioscience, Inc. agreed to acquire Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.	21-05-16	CI
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-03-11	CI
Aerpio Pharmaceuticals Continues to Evaluate Strategic Alternatives	21-03-10	CI
Aerpio Pharmaceuticals : Quantum Leap Healthcare to Discontinue Testing of Aerpio Pharmaceutical's Razuprotafib in COVID Trial	21-03-05	MT
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’S Razuprotafib in I-Spy Covid Trial	21-03-05	CI
Aerpio Pharmaceuticals, Inc. Plans to Terminate Kevin Peters as Chief Scientific Officer and Chief Medical Officer	21-02-01	CI
After Hours Watch List Scorecard: ISR, TATT, ARPO	21-01-06	MT
Aerpio Pharmaceuticals Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	21-01-06	CI
MT Newswires After Hours Watch List: ISR, TATT, ARPO	21-01-05	MT
Aerpio Pharmaceuticals : Pharma Starts Strategic Review To Boost Shareholder Value	21-01-05	MT
Aerpio Pharmaceuticals, Inc. Announces Strategic Review After Topline Results from Razuprotafib Glaucoma Phase 2 Trial	21-01-05	CI
AERPIO PHARMACEUTICALS : HC Wainwright Adjusts Aerpio Pharmaceuticals' Price Target to $1.50 From $2, Keeps at Neutral	20-12-14	MT
Aerpio Pharmaceuticals, Inc. Announces Topline Results from Razuprotafib Glaucoma Phase 2 Trial	20-12-11	CI
Transcript : Aerpio Pharmaceuticals, Inc., Q3 2020 Earnings Call, Nov 10, 2020	20-11-10
Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19	20-10-26	CI

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.

Sector

More about the company

Aerpio Pharmaceuticals

Equities

ARPO

US00810B1052

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

Latest news about Aerpio Pharmaceuticals

Chart Aerpio Pharmaceuticals

Company Profile